Pages that link to "Q40810228"

The following pages link to Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model (Q40810228):

Displaying 17 items.

• Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model. (Q37287661) (← links)
• Is a New Standard Needed for Diffusion Methods for In Vitro Susceptibility Testing of Fosfomycin against Pseudomonas aeruginosa? (Q38367466) (← links)
• Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae (Q38944862) (← links)
• Fosfomycin: Mechanism and Resistance (Q39071416) (← links)
• Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model (Q39704722) (← links)
• Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers (Q40166194) (← links)
• In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. (Q40257051) (← links)
• Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae (Q49196415) (← links)
• Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model. (Q49667957) (← links)
• Molecular insights into fosfomycin resistance in Escherichia coli (Q50950504) (← links)
• Pharmacokinetics and Pharmacodynamics of Fosfomycin and its Activity against ESBL-, Plasmid-mediated AmpC- and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model (Q51734361) (← links)
• Polymyxin B and Fosfomycin Thwart KPC-producing Klebsiella pneumoniae in the Hollow Fibre Infection Model. (Q51746965) (← links)
• Determination of the dynamically-linked indices of fosfomycin for Pseudomonas aeruginosa in the Hollow Fiber Infection Model (HFIM). (Q52629704) (← links)
• Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. (Q52695014) (← links)
• Individualising Therapy to Minimize Bacterial Multidrug Resistance. (Q53070940) (← links)
• New perspectives for reassessing fosfomycin: applicability in current clinical practice. (Q64945950) (← links)
• Deciphering pharmacokinetics and pharmacodynamics of fosfomycin (Q92311237) (← links)